

<p align="center">IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</p>	<i>Application No.</i>	(to be assigned) US National Phase of PCT/FI01/00103
	<i>Filing Date</i> <i>Intl. Filing Date</i>	22 February 2002 06 February 2001
	<i>First Named Inventor</i>	Jussi KAUHANEN
	<i>Group Art Unit</i>	
	<i>Examiner Name</i>	
	<i>Attorney Docket No.</i>	2630-114
<i>Title of the Invention:</i> DIAGNOSIS OF A PERSON'S RISK OF DEVELOPING ALCOHOLISM		

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
 Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-identified U.S. National Phase of PCT/FI01/00103, filed concurrently herewith, please amend the application as shown on the attached pages.

IN THE SPECIFICATION:

Please insert the new paragraph found on the following pages after line 1 on page 1.

IN THE CLAIMS:

Please amend claims 1, 2, 3, 4 and 7 as shown on the following pages.

Marked-up copies of the original text of the amended claims are attached to this preliminary amendment. Material inserted is indicated by underlining and material deleted is enclosed in brackets.

U.S. National Phase of PCT/FI01/00103

22 February 2002

Page 2

New Paragraph of Specification for Insertion After Line 1 of Page 1

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a national stage filing under 35 U.S.C. §371 of PCT/FI01/00103 filed on 6 February 2001. The present application is further related to U.S. provisional patent application Serial No. 60/219,324 filed on 21 March 2000, to which priority is claimed under 35 U.S.C. §119(e).

Clean Copy of Amended Claims

1 (amended). A method for diagnosing a person's susceptibility for having a risk for the development of alcoholism, said method comprising determining whether said subject has a polymorphism in the signal peptide part of the human preproNPY, said polymorphism comprising a substitution of proline for leucine at position 7 in the signal peptide part of said human preproNPY, said polymorphism being indicative of a risk for the development of alcoholism.

2 (amended). The method according to claim 1 wherein said polymorphism in the signal peptide part of the human preproNPY of said subject is determined by subjecting a position 7 allele specific oligonucleotide probe to a sample from said subject, said sample comprising a target polynucleotide of said human preproNPY.

3 (amended). The method according to claim 1 wherein said polymorphism in the signal peptide part of the human preproNPY of said subject is determined by immunoassay where a sample from said subject is contacted with an antibody capable of binding the signal peptide part of said human preproNPY or said NPY peptide associated with any other cleavage product of said human preproNPY.

4 (amended). A method for treating a person, diagnosed for having a risk for the development of alcoholism according to claim 1, for the prevention of developing alcoholism or for alleviating or curing alcoholism, comprising administering to said person an effective amount of an agent counteracting the influence of the mutated NPY gene.

7 (amended). A method for treating a person, diagnosed for having a risk for the development of alcoholism according to claim 1, for the prevention of developing alcoholism or for alleviating or curing alcoholism, comprising subjecting the person to specific gene therapy aimed to repair the mutated NPY gene sequence.


U.S. National Phase of PCT/FI01/00103

22 February 2002

Page 2

REMARKS

The specification has been amended to insert a cross reference to related applications. The amendments to the claims are made to correct minor typographical errors, to remove multiple dependencies and to more clearly describe the polymorphism, thus placing the claims in order for examination. No new matter has been added by these amendments, and their entry is therefore requested.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Registration No. 28,957				
SIGNATURE				DATE	22 FEBRUARY 2002
Address	Rothwell, Figg, Ernst & Manbeck Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

Attachments: Marked-Up Copies of Amendments

Amended Claims - Changes made

1 (amended). A method for diagnosing a person's susceptibility for having a risk for the development of alcoholism, said method comprising determining whether said subject has a polymorphism in the signal peptide part of the human preproNPY, said polymorphism comprising [the substitution] a substitution of proline for leucine at [the] position 7 [leucine for proline] in the signal peptide part of said human preproNPY, said polymorphism being indicative of a risk for the development of alcoholism.

2 (amended). The method according to claim 1 wherein said polymorphism in the signal peptide part of the human preproNPY [at] of said subject is determined by subjecting a position 7 allele specific oligonucleotide probe to a sample from said subject, said sample comprising a target polynucleotide of said human preproNPY.

3 (amended). The method according to claim 1 wherein said polymorphism in the signal peptide part of the human preproNPY [at] of said subject is determined by immunoassay where a sample from said subject is contacted with an antibody capable of binding the signal peptide part of said human preproNPY or said NPY peptide associated with any other cleavage product of said human preproNPY.

4 (amended). A method for treating a person, diagnosed for having a risk for the development of alcoholism according to claim 1, [2 or 3,] for the prevention of developing [alcoholismor] alcoholism or for alleviating or curing alcoholism, comprising administering to said person an effective amount of an agent counteracting the influence of the mutated NPY gene.

7 (amended). A method for treating a person, diagnosed for having a risk for the development of alcoholism according to claim 1, [2 or 3,] for the prevention of developing alcoholism or for alleviating or curing alcoholism, comprising subjecting the person to specific gene therapy aimed to repair the mutated NPY gene sequence.

10069129.052302



ENTERED

PCT10

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/069,129

DATE: 03/07/2002

TIME: 15:28:56

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\03072002\J069129.raw

```

3 <110> APPLICANT: Jussi Kauhanen, Matti Karvonen, Ullamari Pesonen, Markku Koulu, Matti
4      Uusitupa
W--> 5 <120> TITLE OF INVENTION: Diagnosis of a Person's Risk of Developing
W--> 6      Alcoholism Based on Leucine7 to Proline 7 Polymorphism in the Prepro-
W--> 7      Neuropeptide
W--> 8      Y Gene, and methods for the prevention and Treatment of Alcoholism.
W--> 10 <130> FILE REFERENCE:
C--> 12 <140> CURRENT APPLICATION NUMBER: US/10/069,129
C--> 13 <141> CURRENT FILING DATE: 2002-02-22
W--> 15 <150> PRIOR APPLICATION NUMBER:
W--> 16 <151> PRIOR FILING DATE:
18 <160> NUMBER OF SEQ ID NOS: 6
20 <170> SOFTWARE: PatentIn Ver. 2.0
22 <210> SEQ ID NO: 1
23 <211> LENGTH: 325
24 <212> TYPE: DNA
25 <213> ORGANISM: Homo sapiens
27 <400> SEQUENCE: 1
28 ccgcttcttc aggcagtgcc tggggcggga ggggtggggt gtgggtgggt ccctaagtcg 60
30 aactcgtgc ggctgcggt ccagccccct ccccccgcga ctcagggcg ggaagtggcg 120
32 ggtgggagtc acccaagcgt gactgcccga ggcccctcct gccgcggcga ggaagctcca 180
34 taaaagccct gtcgcgacct gctctctgca ccccatccgc tggctctcac cctcgggaga 240
36 cgtcgcgccg acagcatagt acttgccgcc cagccacgcc cgcgcgccag ccaccgtgag 300
38 tgctacgacc cgtctgtcta ggggt 325
41 <210> SEQ ID NO: 2
42 <211> LENGTH: 247
43 <212> TYPE: DNA
44 <213> ORGANISM: Homo sapiens
46 <400> SEQUENCE: 2
47 cccgtccgtt gaggcttctg tgctgcaga tgctaggtaa caagcgactg gggctgtccg 60
49 gactgacct cgccctgtcc ctgctcgtgt gcctgggtgc gctggccgag gcgtacctcc 120
51 ccaagccgga caaccgggc gaggacgcac cagcggagga catggccaga tactactcag 180
53 cgctgcgaca ctacatcaac ctcacacca ggcagaggtg ggtgggaccg cgggaccgat 240
55 tccggga 247
58 <210> SEQ ID NO: 3
59 <211> LENGTH: 142
60 <212> TYPE: DNA
61 <213> ORGANISM: Homo sapiens
63 <400> SEQUENCE: 3
64 acttgcttta aaagactttt tttttccag atatggaaaa cgatctagcc cagagacact 60
66 gatttcagac ctcttgatga gagaaagcac agaaaatgtt cccagaactc ggtatgacaa 120
68 ggcttgatg ggggacattg tt 142
71 <210> SEQ ID NO: 4

```

10069129_062802

RAW SEQUENCE LISTING

DATE: 03/07/2002

PATENT APPLICATION: US/10/069,129

TIME: 15:28:56

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\03072002\J069129.raw

```

72 <211> LENGTH: 300
73 <212> TYPE: DNA
74 <213> ORGANISM: Homo sapiens
76 <400> SEQUENCE: 4
77 cettacatgc tttgcttctt atgttttaca ggcttgaaga ccttgcaatg tggatgatggg 60
79 aaatgagact tgctctctgg ccttttccta ttttcagccc atattttcatc gtgtaaaacg 120
81 agaattccacc catcctacca atgcatgcag ccactgtgct gaattctgca atgttttctt 180
83 ttgtcatcat tgtatatatg tgtgttttaa taaagtatca tgcattcaaa agtgtatcct 240
85 cctcaatgaa aaatctatta caatagttag gattattttc gttaaactta ttattaacaa 300
88 <210> SEQ ID NO: 5
89 <211> LENGTH: 551
90 <212> TYPE: DNA
91 <213> ORGANISM: Homo sapiens
93 <220> FEATURE:
94 <221> NAME/KEY: CDS
95 <222> LOCATION: (87)..(377)
97 <220> FEATURE:
98 <221> NAME/KEY: sig_peptide
99 <222> LOCATION: (87)..(170)
101 <400> SEQUENCE: 5
102 accccatccg ctggctctca cccctcggag acgctcggcc gacagcatag tacttgccgc 60
104 ccagccacgc ccgcgcgcca gccacc atg cta ggt aac aag cga ctg ggg ctg 113
105 Met Leu Gly Asn Lys Arg Leu Gly Leu
106 1 5
108 tcc gga ctg acc ctc gcc ctg tcc ctg ctc gtg tgc ctg ggt gcg ctg 161
109 Ser Gly Leu Thr Leu Ala Leu Ser Leu Leu Val Cys Leu Gly Ala Leu
110 10 15 20 25
112 gcc gag gcg tac ccc tcc aag ccg gac aac ccg ggc gag gac gca cca 209
113 Ala Glu Ala Tyr Pro Ser Lys Pro Asp Asn Pro Gly Glu Asp Ala Pro
114 30 35 40
116 gcg gag gac atg gcc aga tac tac tcg gcg ctg cga cac tac atc aac 257
117 Ala Glu Asp Met Ala Arg Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn
118 45 50 55
120 ctc atc acc agg cag aga tat gga aaa cga tcc agc cca gag aca ctg 305
121 Leu Ile Thr Arg Gln Arg Tyr Gly Lys Arg Ser Ser Pro Glu Thr Leu
122 60 65 70
124 att tca gac ctc ttg atg aga gaa agc aca gaa aat gtt ccc aga act 353
125 Ile Ser Asp Leu Leu Met Arg Glu Ser Thr Glu Asn Val Pro Arg Thr
126 75 80 85
128 cgg ctt gaa gac cct gca atg tgg tgatgggaaa tgagacttgc tctctggcct 407
129 Arg Leu Glu Asp Pro Ala Met Trp
130 90 95
132 tttcctattt tcagcccata tttcatcgtg taaaacgaga atccacccat cctaccaatg 467
134 catgcagcca ctgtgctgaa ttctgcaatg ttttcttttg tcatcattgt atatatgtgt 527
136 gtttaaataa agtatcatgc attc 551
139 <210> SEQ ID NO: 6
140 <211> LENGTH: 97
141 <212> TYPE: PRT
142 <213> ORGANISM: Homo sapiens

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/069,129

DATE: 03/07/2002

TIME: 15:28:56

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\03072002\J069129.raw

```

144 <400> SEQUENCE: 6
145 Met Leu Gly Asn Lys Arg Leu Gly Leu Ser Gly Leu Thr Leu Ala Leu
146   1           5           10           15
148 Ser Leu Leu Val Cys Leu Gly Ala Leu Ala Glu Ala Tyr Pro Ser Lys
149           20           25           30
151 Pro Asp Asn Pro Gly Glu Asp Ala Pro Ala Glu Asp Met Ala Arg Tyr
152           35           40           45
154 Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr Arg Gln Arg Tyr
155           50           55           60
157 Gly Lys Arg Ser Ser Pro Glu Thr Leu Ile Ser Asp Leu Leu Met Arg
158   65           70           75           80
160 Glu Ser Thr Glu Asn Val Pro Arg Thr Arg Leu Glu Asp Pro Ala Met
161           85           90           95
163 Trp

```


VERIFICATION SUMMARY

PATENT APPLICATION: US/10/069,129

DATE: 03/07/2002

TIME: 15:28:57

Input Set : A:\pto.vsk.txt

Output Set: N:\CRF3\03072002\J069129.raw

L:5 M:283 W: Missing Blank Line separator, <120> field identifier
L:10 M:201 W: Mandatory field data missing, <130> FILE REFERENCE
L:12 M:270 C: Current Application Number differs, Replaced Application Number
L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:15 M:256 W: Invalid Numeric Header Field, <150> PRIOR APPLICATION NUMBER:
L:16 M:256 W: Invalid Numeric Header Field, Wrong Prior FILING DATE:YYYY-MM-DD